Lineage Cell Therapeutics Stock Earnings Reports

Key points for investors:

- OpRegen (lead program): Management remains confident in the program based on their Phase 1/2a data and corroborating results from other RPE transplant efforts. Roche/Genentech continue to advance the GAlette study (now 17 sites), and Genentech has recently described the approach as potentially disease modifying. Lineage is awaiting partner-driven decisions on next-stage multicenter, controlled testing but stresses the strength of long-term safety/efficacy data and proprietary delivery/manufacturing capabilities.

- Manufacturing (AlloSCOPE) is central to Lineage's strategy: The company emphasized the importance of establishing robust, scalable, reproducible cell banking and production before clinical expansion. Management asserts the platform can produce very large numbers of vials and materially lower cost-per-dose, which they view as a competitive and commercial advantage.

- New and advancing pipeline programs: COR1 (corneal endothelial cells) has been advanced rapidly to preclinical development with successful manufacture of off-the-shelf CENCs; goal is translational models then IND/human testing. ILT1 (AlloSCOPE 5D) targets the islet cell scale problem for T1D by focusing on large-scale production of homogenized undifferentiated pluripotent cells as feedstock for differentiation. OPC1 (oligodendrocyte progenitors for SCI) is enrolling chronic patients in the DOSED device study, with the first chronic patient approaching 1-year follow-up; device performance to date has shown no unexpected procedure/product/device-related AEs. ReSonance (auditory neurons) has completed engineering runs and is progressing with Demant under a funded collaboration (up to $12M).

- Partnerships and de-risking: Demant funds ReSonance preclinical development; Roche/Genentech remain the OpRegen partner. The company is pursuing additional collaborations selectively.

- Organizational and scientific support: New senior clinical hire (Dr. Priyantha Harath) and formation of a Scientific Advisory Board with founding member Dr. Joachim Froebus.

- Financials and runway: Cash balance was $53.4M at 3/31/26, expected to fund operations into 2028. Additional potential financing includes ~$32M from exercise of existing warrants (with acceleration conditions tied to OpRegen advancement) and up to $615M of development/commercial milestones under the Roche-Genentech agreement. Q1 revenue was $1.7M; operating expenses increased (R&D and G&A), net loss was $4.8M ($0.02 basic EPS). Management emphasizes disciplined spend and continued focus on manufacturing-led value creation.

- Upcoming catalysts to monitor: any public decision from Roche/Genentech on OpRegen multicenter trial, OPC1 initial chronic patient 1-year update, ReSonance go/no-go/engineering-to-GMP progress, COR1 translational/IND timeline, ILT1 scale-up milestones, new SAB appointments, patent issuances, and partnership activity.